Bristol Myers Squibb reports lung cancer data: what it means for Bristol Myers Squibb stock

Published on 10/25/2026 at 17:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock costs EUR 55.35 in weekend trading on October 25, 2026. The companies reported Phase 2 lung cancer data.

Clinical update and trading dates

Bristol Myers Squibb and BioNTech reported Phase 2 lung cancer data on October 25, 2026.
Bristol Myers Squibb stock trades in weekend trading at Lang & Schwarz at EUR 55.35 at 5:21 p.m. CEST on October 25, 2026.
The next Xetra session is scheduled for October 26, 2026.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

On October 25, 2026, Bristol Myers Squibb and BioNTech reported first data from the global Phase 2 ROSETTA Lung-107 trial evaluating pumitamig with docetaxel in metastatic non-small cell lung cancer.

Bristol Myers Squibb stock was at EUR 55.35 in weekend trading at Lang & Schwarz at 5:21 p.m. CEST on October 25, 2026. The quote page lists a bid of EUR 55.24 and an ask of EUR 55.46.

The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.

Clinical development

The October 25 release said pumitamig plus docetaxel produced a confirmed objective response rate of 36.7 percent among 30 efficacy-evaluable patients. Median progression-free survival was 6.9 months in the overall treated population of 50 patients. The release also reported a disease control rate of 90.0 percent and said the data were presented at the European Society for Medical Oncology Congress 2026 in Madrid.

In a separate October 12 release, Bristol Myers Squibb announced positive topline results from the interim analysis of the Phase 3 ACTION-1 trial for RYZ101. The company said the study met its primary endpoint of progression-free survival.

Market context: Market report S&P 500.